{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tang J"],"funding":["NIBIB NIH HHS","HHS | NIH | National Cancer Institute","NHLBI NIH HHS","Foundation for the National Institutes of Health","National Institute for Health Research (NIHR)","NCI NIH HHS"],"pagination":["E6731-E6740"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5098679"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["113(44)"],"pubmed_abstract":["Immunological complexity in atherosclerosis warrants targeted treatment of specific inflammatory cells that aggravate the disease. With the initiation of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascular disease treatment enters a new era. We here propose a radically different approach: implementing and evaluating in vivo a combinatorial library of nanoparticles with distinct physiochemical properties and differential immune cell specificities. The library's nanoparticles are based on endogenous high-density lipoprotein, which can preferentially deliver therapeutic compounds to pathological macrophages in atherosclerosis. Using the apolipoprotein E-deficient (Apoe<sup>-/-</sup>) mouse model of atherosclerosis, we quantitatively evaluated the li"],"journal":["Proceedings of the National Academy of Sciences of the United States of America"],"pubmed_title":["Immune cell screening of a nanoparticle library improves atherosclerosis therapy."],"pmcid":["PMC5098679"],"funding_grant_id":["R01 HL128264","P30 CA008748","R01 HL129433","R01 CA155432","R21 HL123433","P01 HL131478","R01 HL095612","T32 HL098129","R01 HL118440","K25 EB016673","R01 EB009638","P30 CA008748-50","R01HL125703","R01 HL125703"],"pubmed_authors":["Sanchez-Gaytan BL","Nahrendorf M","Perez-Medina C","Fayad ZA","Fay F","Calcagno C","Menon A","Zhao Y","Fisher EA","Mulder WJ","Tang J","Tsimikas S","Braza MS","Moore KJ","Swirski FK","Ouimet M","Duivenvoorden R","Longo VA","Storm G","Reiner T","Baxter S","Abdel-Atti D","Alaarg A"],"additional_accession":[]},"is_claimable":false,"name":"Immune cell screening of a nanoparticle library improves atherosclerosis therapy.","description":"Immunological complexity in atherosclerosis warrants targeted treatment of specific inflammatory cells that aggravate the disease. With the initiation of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascular disease treatment enters a new era. We here propose a radically different approach: implementing and evaluating in vivo a combinatorial library of nanoparticles with distinct physiochemical properties and differential immune cell specificities. The library's nanoparticles are based on endogenous high-density lipoprotein, which can preferentially deliver therapeutic compounds to pathological macrophages in atherosclerosis. Using the apolipoprotein E-deficient (Apoe<sup>-/-</sup>) mouse model of atherosclerosis, we quantitatively evaluated the li","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Nov","modification":"2025-04-26T15:08:26.416Z","creation":"2019-03-27T02:28:26Z"},"accession":"S-EPMC5098679","cross_references":{"pubmed":["27791119"],"doi":["10.1073/pnas.1609629113"]}}